J&J files in Europe for first-line Imbruvica use in CLL; First-to-market races mean small R&D leads can pay off big;

> Johnson & Johnson's ($JNJ) Janssen unit submitted an application for expanded European approval of its blood cancer drug Imbruvica, as a therapy for previously untreated patients with chronic lymphocytic leukemia. Release

> These days, it's common to see several drugs racing for a first-in-class approval, which means that small accelerations in R&D can yield big payoffs, a Tufts University study found. Report

> Johnson & Johnson and GlaxoSmithKline's ($GSK) ViiV Healthcare joint venture touted data from Phase II studies of two long-acting injectable versions of now-daily HIV pills. Release | Report

And Finally ... Mylan ($MYL) won U.S. antitrust approval to buy Perrigo ($PRGO), provided it sells off rights to several generic products. Release

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

AbbVie and Allergan's merger may create the fourth-largest drugmaker in the world, but it could also create opportunities for other drugmakers.